Payment overview · 2025
General Payments
$272.96
3 reported records · 2 companies
Healthcare provider profile · identity verified
Inna Janas, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GREAT NECK, NY · NPI 1972698736
Verified facts
What the public records show
CMS Open Payments records show Inna Janas, M.D. received $272.96 in general payments during 2025 across 3 reported records.
ARGENX US, INC. accounted for 91.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Nuplazid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $249.31 | 91.3% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $23.65 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $272.96 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $249.31 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $23.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 668 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 446 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 295 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 279 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 274 | 18 |
| Lisinopril | Lisinopril | 269 | 18 |
| Gabapentin | Gabapentin | 268 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 266 | 30 |
| Eliquis | Apixaban | 263 | 24 |
| Furosemide | Furosemide | 232 | 22 |
| Famotidine | Famotidine | 224 | 17 |
| Metformin Hcl | Metformin Hcl | 187 | 16 |
| Januvia | Sitagliptin Phosphate | 184 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 12 |
| Losartan Potassium | Losartan Potassium | 151 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 150 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 12 |
| Mirtazapine | Mirtazapine | 115 | 16 |
| Carvedilol | Carvedilol | 114 | suppressed |
| Omeprazole | Omeprazole | 103 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 88 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | suppressed |
| Potassium Chloride | Potassium Chloride | 75 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 73 | suppressed |
| Amantadine | Amantadine Hcl | 70 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 66 | suppressed |
| Allopurinol | Allopurinol | 65 | suppressed |
| Xarelto | Rivaroxaban | 62 | suppressed |
| Latanoprost | Latanoprost | 61 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 57 | suppressed |
| Torsemide | Torsemide | 57 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 54 | suppressed |
| Levetiracetam | Levetiracetam | 52 | suppressed |
| Risperidone | Risperidone | 49 | suppressed |
| Atenolol | Atenolol | 48 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 46 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 21 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 41 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Nystatin | Nystatin | 35 | 16 |
| Brimonidine Tartrate | Brimonidine Tartrate | 34 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 13 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Budesonide | Budesonide | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 21 |
| Simvastatin | Simvastatin | 26 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Roflumilast | Roflumilast | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Cilostazol | Cilostazol | 24 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Hydroxyurea | Hydroxyurea | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Repaglinide | Repaglinide | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 21 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Meloxicam | Meloxicam | 15 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 14 | suppressed |
| Brinzolamide | Brinzolamide | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Admelog Solostar | Insulin Lispro | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $272.96 · 3 records | ARGENX US, INC. | NUPLAZID, VYVGART | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuplazid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error